Ranibizumab Yields 15-Letter Gain In VA In Patients Treated For DME, Study Shows

Friday, April 1, 2011

Comments

Ocular Surgery News

Results of the second of two phase 3 clinical trials showed that ranibizumab met its primary endpoint in patients being treated for diabetic macular edema, according to a news release from Genentech.

Full Story

Retina Products and Equipment »

The patient depicted in the photo was scheduled for a surgical procedure which was aborted at the beginning of the case. The photo was taken 2 weeks after the scheduled surgery. What was the most likely intraoperative event?
1. post injection retrobulbar hematoma
2. infection from nonsterile instruments
3. cautery fire
4. allergic reaction to surgical drapes
Check The Answer

CareCloud Central
CareCloud Central is a medical practice ... view product
VISUPLAN 500 Non-Contact Tonometer
The measurement of intraocular pressure ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Ranibizumab Yields 15-Letter Gain In VA In Patients Treated For DME, Study Shows

Comments

Related Categories

Retina Products and Equipment »

Quick Quiz

The patient depicted in the photo was scheduled for a surgical procedure which was aborted at the beginning of the case. The photo was taken 2 weeks after the scheduled surgery. What was the most likely intraoperative event?

AdGlare RMR Ad

Featured Products

CareCloud Central

VISUPLAN 500 Non-Contact Tonometer

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us